Paper32010641
Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets.
Wang H and 9 others. Front Cell Infect Microbiol, 2019. Cited by 170 papers, by iCite.
Cite this record
ConductScience Library. Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets. Papers, record 32010641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32010641
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Fecal Microbiota Transplantation | Major topic |
| Insulin Resistance | Major topic |
| Animals | |
| Apoptosis | |
| Blood Glucose | |
| Cytokines | |
| Diabetes Mellitus, Experimental | |
| Diet, High-Fat | |
| Energy Metabolism | |
| Gastrointestinal Microbiome | |
| Glycated Hemoglobin | |
| Inflammation | |
| Insulin | |
| Islets of Langerhans | |
| Mice |
Source PubMed
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28280484 | Variable Colonization after Reciprocal Fecal Microbiota Transfer between Mice with Low and High Richness Microbiota. | Front Microbiol | 2017 | https://conductscience.org/library/papers/28280484 | PubMed |
| 2 | 28087657 | European consensus conference on faecal microbiota transplantation in clinical practice. | Gut | 2017 | https://conductscience.org/library/papers/28087657 | PubMed |
| 3 | 29299635 | Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function. | Diabetologia | 2018 | https://conductscience.org/library/papers/29299635 | PubMed |
| 4 | 30238182 | Probiotic intervention in infancy is not associated with development of beta cell autoimmunity and type 1 diabetes. | Diabetologia | 2018 | https://conductscience.org/library/papers/30238182 | PubMed |
| 5 | 30296461 | Reducing inflammation through delivery of lentivirus encoding for anti-inflammatory cytokines attenuates neuropathic pain after spinal cord injury. | J Control Release | 2018 | https://conductscience.org/library/papers/30296461 | PubMed |
| 6 | 29789539 | Proteasomal degradation of the histone acetyl transferase p300 contributes to beta-cell injury in a diabetes environment. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/29789539 | PubMed |
| 7 | 20140211 | Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. | PLoS One | 2010 | https://conductscience.org/library/papers/20140211 | PubMed |
| 8 | 12502499 | Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. | Diabetes | 2003 | https://conductscience.org/library/papers/12502499 | PubMed |
| 9 | 17190852 | A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. | Physiol Genomics | 2007 | https://conductscience.org/library/papers/17190852 | PubMed |
| 10 | 27252163 | Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. | Physiology (Bethesda) | 2016 | https://conductscience.org/library/papers/27252163 | PubMed |
| 11 | 23955772 | UPARSE: highly accurate OTU sequences from microbial amplicon reads. | Nat Methods | 2013 | https://conductscience.org/library/papers/23955772 | PubMed |
| 12 | 29472432 | Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes. | Diabetes Care | 2018 | https://conductscience.org/library/papers/29472432 | PubMed |
| 13 | 31250122 | Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes? | Curr Diab Rep | 2019 | https://conductscience.org/library/papers/31250122 | PubMed |
| 14 | 26098218 | Engineering the gut microbiota to treat hyperammonemia. | J Clin Invest | 2015 | https://conductscience.org/library/papers/26098218 | PubMed |
| 15 | 24645635 | Early life events influence whole-of-life metabolic health via gut microflora and gut permeability. | Crit Rev Microbiol | 2015 | https://conductscience.org/library/papers/24645635 | PubMed |
| 16 | 30467295 | Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30467295 | PubMed |
| 17 | 30052036 | Human Mesenchymal Stem Cell Derived Exosomes Alleviate Type 2 Diabetes Mellitus by Reversing Peripheral Insulin Resistance and Relieving β-Cell Destruction. | ACS Nano | 2018 | https://conductscience.org/library/papers/30052036 | PubMed |
| 18 | 28609252 | Fecal microbiota transplantation in metabolic syndrome: History, present and future. | Gut Microbes | 2017 | https://conductscience.org/library/papers/28609252 | PubMed |
| 19 | 23023125 | A metagenome-wide association study of gut microbiota in type 2 diabetes. | Nature | 2012 | https://conductscience.org/library/papers/23023125 | PubMed |
| 20 | 30328245 | Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT). | Diabetes Obes Metab | 2019 | https://conductscience.org/library/papers/30328245 | PubMed |
Cited by131
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 170 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42511768 | Advancing Personalized Medicine in Gestational Diabetes Mellitus Management Through Gut Microbiota Insights. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511768 | PubMed |
| 42077461 | Faecal microbiota transplantation and glucolipid metabolic disorders: the interventional role of gut microbiota. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42077461 | PubMed |
| 42015346 | Gut microbiome and metabolic health: mechanisms and precision interventions. | Gut Microbes | 2026 | https://conductscience.org/library/papers/42015346 | PubMed |
| 41949970 | New therapeutic approaches based on modulation of the intestinal microbiota to correct dysbiosis in patients with type 2 diabetes. | Tunis Med | 2025 | https://conductscience.org/library/papers/41949970 | PubMed |
| 41904207 | Impact of Lactobacillus johnsonii on glycemic control and lipid metabolism in type 2 diabetes with circadian disruption. | Sci Rep | 2026 | https://conductscience.org/library/papers/41904207 | PubMed |
| 41694562 | Targeting the gut microbiome for type 2 diabetes management: a scoping review of systematic reviews and meta-analyses. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/41694562 | PubMed |
| 41598218 | Systematic Review: Exploring Inter-Species Variability in Diabetes Mellitus for Translational Medicine. | Life (Basel) | 2025 | https://conductscience.org/library/papers/41598218 | PubMed |
| 41586316 | Car@PLGA-NPs target gut microbiota-ER stress axis to combat diabetes. | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/41586316 | PubMed |
| 41487501 | Recent advances in natural polysaccharides for type 2 diabetes management: sources, structural characteristics, and mechanistic insights. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/41487501 | PubMed |
| 41459531 | Targeting the TLR4 axis with microbiota-oriented interventions and innovations in diabetes therapy: a narrative review. | Front Immunol | 2025 | https://conductscience.org/library/papers/41459531 | PubMed |
| 41395840 | Targeted Therapy for Gut Microbiota: Candidates for a Novel Strategy to Ameliorate Type 2 Diabetes Mellitus. | Microb Biotechnol | 2025 | https://conductscience.org/library/papers/41395840 | PubMed |
| 41269457 | Attenuating Neurotoxicity Through Fecal Microbiota Transplant: Mechanisms and Therapeutic Potential. | Mol Neurobiol | 2025 | https://conductscience.org/library/papers/41269457 | PubMed |
| 41219653 | Gut Microbiota and Chronic Kidney Disease: A Complex Interplay with Implications for Diagnosis and Treatment. | Probiotics Antimicrob Proteins | 2026 | https://conductscience.org/library/papers/41219653 | PubMed |
| 40957477 | The eternal struggle between titans: Fecal microbiota transplant (FMT) versus metformin in type 2 diabetes (T2D) gut dysmotility. | J Adv Res | 2026 | https://conductscience.org/library/papers/40957477 | PubMed |
| 40708777 | Gut-Brain Axis in Obesity: How Dietary Patterns Influence Psychological Well-Being and Metabolic Health? | Food Sci Nutr | 2025 | https://conductscience.org/library/papers/40708777 | PubMed |
| 40612440 | Animal studies on the modulation of differential efficacy of polyethylene glycol loxenatide by intestinal flora. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/40612440 | PubMed |
| 40564947 | Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40564947 | PubMed |
| 40550998 | Colonization patterns of intestinal pioneering microbiota of different broiler breeds and their effects on composition of intestinal mucosal barrier during early life. | Sci China Life Sci | 2025 | https://conductscience.org/library/papers/40550998 | PubMed |
| 40528179 | Common mechanisms of Gut microbe-based strategies for the treatment of intestine-related diseases: based on multi-target interactions with the intestinal barrier. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/40528179 | PubMed |
| 40489582 | Glucose Parameters, Inflammation Markers, and Gut Microbiota Changes of Gut Microbiome-Targeted Therapies in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | J Clin Endocrinol Metab | 2025 | https://conductscience.org/library/papers/40489582 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32010641
GET https://conductscience.org/api/papers/v1/32010641/references?page=2